article thumbnail

Re-engineering Cancer Clinical Trials at Scale

MedCity News

Engineers see everything as a system, know how to design under constraints, and recognize the need for trade-offs. Adopting an engineering mindset in oncology research can fix all the broken constituent processes like patient enrollment to systematize clinical trials.

article thumbnail

Beyond Engineering: Integrating UX for Safer and More Efficient Medical Products

MedCity News

While the approach to patient and treatment safety is crucial, there is a notable shift towards processes centered around patients and healthcare professionals. The post Beyond Engineering: Integrating UX for Safer and More Efficient Medical Products appeared first on MedCity News.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

3 Ways to Use an Engineering Mindset to Optimize Patient Access Workflows

MedCity News

In a day of vast innovation, expansion, and acquisitions, an engineering mindset can bring a unique and effective approach to thinking across the system, evaluating the current and future state, standardizing on best practices, and considering upstream and downstream workflows.

article thumbnail

Novome gets $43.5M boost for its engineered microbiome therapies

MedCity News

Novome Biotechnologies — a biotech that CEO Blake Wise says is only company to pursue engineered cell therapy with microbes for the treatment of chronic diseases — raised $43.5 million in Series B funds.

article thumbnail

Penn spinout Capstan aims for next cell therapy frontier: in vivo cell engineering

MedCity News

Capstan Therapeutics, a University of Pennsylvania spinout, is now out of stealth with technology that could enable new medicines that work by engineering cells inside of a patient.

article thumbnail

First patient receives new engineered mRNA epigenetic

European Pharmaceutical Review

revealed the first patient to be dosed with OTX-2002, the first programmable mRNA therapeutic for c-Myc (MYC) oncogene overexpression, which targets cancer cells while sparing healthy cells. Biotech firm Omega Therapeutics, Inc. The investigation is expected to enrol around 190 volunteers in the US, Asia and Europe.

article thumbnail

Novartis warns of two patients deaths after dosing with gene therapy Zolgensma

MedCity News

Liver complications are a known side effect risk of Zolgensma and other genetic medicines that are delivered by engineered viruses. The two deaths reported following treatment with Novartis’s Zolgensma mark the first fatal cases of acute liver failure associated with the gene therapy.